EOFLOW Co.,Ltd. (KOSDAQ:294090)
South Korea · Delayed Price · Currency is KRW 1,490.00
-89.00 (-5.64%)
At close: Mar 21, 2025
EOFLOW Revenue
EOFLOW had revenue of 1.60B KRW in the quarter ending September 30, 2025, with 12.27% growth. This brings the company's revenue in the last twelve months to 3.98B, down -36.64% year-over-year. In the year 2024, EOFLOW had annual revenue of 5.03B, down -23.65%.
Revenue (ttm)
3.98B
Revenue Growth
-36.64%
P/S Ratio
12.85
Revenue / Employee
n/a
Employees
62
Market Cap
51.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.03B | -1.56B | -23.65% |
| Dec 31, 2023 | 6.59B | -118.66M | -1.77% |
| Dec 31, 2022 | 6.71B | 6.01B | 867.57% |
| Dec 31, 2021 | 693.27M | 671.61M | 3,101.49% |
| Dec 31, 2020 | 21.65M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |